Testosterone therapy and risk of cardiovascular disease in men

JAMA

Volumn 310, Issue 17, 2013, Pages 1805-1806

  Cappola, Anne R ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; TESTOSTERONE;

ANDROGEN DEFICIENCY; ANDROGEN THERAPY; ANGIOCARDIOGRAPHY; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY DISEASE; DEATH; DRUG SAFETY; EDITORIAL; GEL; HEART INFARCTION; HUMAN; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SEXUAL FUNCTION; TESTOSTERONE BLOOD LEVEL; WELLBEING;

EID: 84887093067     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2013.280387     Document Type: Editorial

References (5)

1. Baillargeon J, Urban RJ, Ottenbacher KJ, Pierson KS, Goodwin JS. Trends in androgen prescribing in the United States, 2001 to 2011. JAMA Intern Med. 2013;173(15):1465-1466.
2. Vigen R, O'Donnell CI, Barón AE, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013;310(17): doi.10.1001/JAMA.2013.280386.
3. Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. N Engl J Med. 2010;363(2):109-122.
4. Bhasin S, Cunningham GR, Hayes FJ, et al Task Force, Endocrine Society. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010;95(6):2536-2559.
5. Schwartz LM, Woloshin S. Low "t" as in "template": how to sell disease. JAMA Intern Med. 2013;173(15):1460-1462.